Non-Myeloablative Allogeneic Transplantation From Unrelated Donors in Multiple Myeloma

December 27, 2006 updated by: Azienda Ospedaliera San Giovanni Battista
The protocol aims at reducing transplant toxicity and mortality in patients with multiple myeloma.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Primary end points are engraftment and non-relapse mortality. Secondary end points are disease response, overall survival, progression and event free survivals. Patient eligibility criteria.

Inclusion criteria included:

  • Diagnosis of Durie-Salmon stage IIA-IIIB multiple myeloma
  • Age > 18 and ≤ 65 years at the start of the donor search
  • Presence of concurrent co-morbidities precluding myeloablative conditioning or refusal to undergo a conventional allogeneic transplant
  • Capacity to give informed consent

Exclusion criteria included:

  • Age > 65 years
  • Karnofsky performance status score < 60%
  • Progressive disease or stable disease for less than three months
  • Central nervous system (CNS) involvement
  • Left ventricular ejection fraction < 35% or symptomatic heart failure
  • Poorly controlled hypertension
  • Pulmonary dysfunction with diffusing capacity for carbon monoxide (DLCO) < 40% and/or need for continuous oxygen supplementation
  • Abnormal liver disease with a serum bilirubin greater than twice normal or SGOT and/or SGPT greater than four times the upper limits of normal
  • HIV positive patients
  • Pregnancy
  • Refusal to use contraceptive techniques during and for 12 months following treatment

Informed consent is obtained during study registration from each patient according to the Institutional Review Boards of the participating centers. The study is conducted according to the Declaration of Helsinki.

Study Type

Interventional

Enrollment

100

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Italy
      • Torino, Italy, 10126
        • Recruiting
        • Divisione Universitaria Ematologia Azienda Ospedaliera S G Battista
        • Principal Investigator:
          • Benedetto Bruno, MD, PhD
        • Sub-Investigator:
          • Luisa Giaccone, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Diagnosis of Durie-Salmon stage IIA-IIIB multiple myeloma
  • Age > 18 and ≤ 65 years at the start of the donor search
  • Presence of concurrent co-morbidities precluding myeloablative conditioning or refusal to undergo a conventional allogeneic transplant
  • Capacity to give informed consent

Exclusion Criteria:

  • Age > 65 years
  • Karnofsky performance status score < 60%
  • Progressive disease or stable disease for less than three months
  • Central nervous system involvement
  • Left ventricular ejection fraction < 35% or symptomatic heart failure
  • Poorly controlled hypertension
  • Pulmonary dysfunction with diffusing capacity for carbon monoxide (DLCO) < 40% and/or need for continuous oxygen supplementation
  • Abnormal liver disease with a serum bilirubin greater than twice normal or SGOT and/or SGPT greater than four times the upper limits of normal
  • HIV positive patients
  • Pregnancy
  • Refusal to use contraceptive techniques during and for 12 months following treatment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Azienda Ospedaliera San Giovanni Battista

Investigators

  • Principal Investigator: Benedetto Bruno, MD, PhD, Divisione di Ematologia _ Azienda Ospedaliera S G Battista di Torino

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2002

Study Completion

October 1, 2006

Study Registration Dates

First Submitted

May 16, 2006

First Submitted That Met QC Criteria

May 16, 2006

First Posted (Estimate)

May 18, 2006

Study Record Updates

Last Update Posted (Estimate)

December 28, 2006

Last Update Submitted That Met QC Criteria

December 27, 2006

Last Verified

December 1, 2006

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MM 1641

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Myeloma

Clinical Trials on Transplantation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe